Clinical field study on anti-malaria treatment ArTiMist™...

Clinical field study on anti-malaria treatment ArTiMist™ successfully completed in 30 children
Berlin, March 5, 2010 – HC Berlin Pharma AG, a company listed on the Open Market of the Frankfurt Stock Exchange, announces the successful completion of the clinical field study on the anti-malaria treatment ArTiMist™ in 30 children in Rwanda.
The study confirmed that sublingual administration of the innovative anti-malaria remedy ArTiMist™ is more beneficial than intravenous treatment.
As a next step, the collected data will be compiled into a comprehensive bio-analytical profile. The relevant report will probably be available at the end of April 2010.
Further information can be found on the website of Eastland Medical Systems Ltd (www.eastlandmedical.com), the principal shareholder of HC Berlin Pharma AG who is contractually obligated to fulfill the regulatory requirements and follow the procedures for the approval of ArTiMist™.
Further information relating to HC Berlin Pharma AG is available at www.hcberlinpharma.ag.
For detailed information please directly contact our Investor Relations team:
esVedra consulting GmbH
t: +49. 89. 28 80 81 33
f: +49. 89. 28 80 81 49
[email protected]